1. Introduction
There is a significant increase in the prevalence of adiposity in young adults [
1] which could lead to the development of adverse health conditions such as obesity, cardiovascular disease and type 2 diabetes later in life [
2,
3]. From an overall health and longevity perspective, lifestyle interventions that help regulate fat mass are likely important for promoting a healthier metabolic phenotype over time [
4,
5].
A recent systematic review and meta-analysis involving over 800 healthy adults (≥ 19 years) showed that resistance exercise (≥ 4 times per week for up to 2 years) decreased fat mass by 0.55 kg (95% CI: -0.75 to -0.34; p<0.0001) and body fat % by 1.46% (95% CI: -1.78 to -1.14; p<0.0001) over time [
6]. These changes may be related to the stimulating effects of resistance exercise on resting metabolic rate [
7], excess post oxygen consumption [
8] and circulating levels of non-esterified fatty acids and by decreasing the respiratory quotient (indicating increased adipocyte lipolysis and/or intramuscular triglyceride oxidation) [
9]. In addition to resistance exercise, supplementing with creatine (methylguanidine acetic acid) may lead to greater reductions in fat mass over time compared to resistance exercise alone. We previously performed a meta-analysis showing that healthy older adults (n=609; 19 studies; ≥ 50 years) who supplemented with creatine (≥ 2 grams/day) and performed resistance exercise (2-3 times/week for up to 1 year) experienced a significant reduction in body fat % (0.55%; CI: -1.08 to -0.03; p=0.04) and a non-significant decrease in fat mass (-0.50 kg; 95% CI: -1.15 to 0.15; p=0.13) compared to resistance exercise alone [
10]. While no mechanisms were determined in this analysis, creatine has the ability to influence whole-body energy expenditure, adipocyte metabolism, thermogenesis, fat bioenergetics and body fat accumulation [
10,
11,
12,
13,
14]. However, the generalizability of these findings may be limited because older adults have a high degree of variability in their responsiveness to resistance exercise and creatine supplementation.
Individual studies examining the efficacy of creatine supplementation and resistance exercise on measures of body fat in healthy younger adults (< 50 years) indicate that creatine has no meaningful effect on fat mass [
15]. Interestingly, in children (n=9) suffering from cancer (acute lymphoblastic leukemia), creatine significantly reduced body fat % over time (p<0.05) [
15]. A limitation of individual studies is that it is typically difficult to obtain adequate statistical power to detect small differences between creatine and placebo over time due to small sample sizes. Combining studies into a meta-analysis helps overcome this limitation by assessing a large cohort of individuals. However, the meta-analytic effects of resistance exercise and creatine supplementation in adults < 50 years of age is unknown. This is important to determine because a common belief held by many exercising individuals is that creatine supplementation increases fat mass over time [
15]. Therefore, the purpose of this systematic review and meta-analysis was to determine the effects of resistance exercise and creatine supplementation on measures of fat mass (i.e., absolute and body fat %) in adults < 50 years of age, while accounting for several associated variables, including creatine dose and duration, and health status.
2. Materials and Methods
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) standards were followed to conduct this systematic review and meta-analysis [
16] and the protocol was registered in the PROSPERO (International Prospective Register of Systematic Reviews) database (CRD:42023416700).
2.1. Search Strategy
From the inception to April 2023, two separate reviewers (K.P. and F.R.) searched PubMed, Scopus, Web of Science, and the Cochrane library, using the following keywords: "creatine supplementation" OR “creatine” OR "creatine monohydrate" AND "body fat*" OR "body composition". The following inclusion criteria was used: (1) studies had to be randomized controlled trials (RCTs); (2) mean age of participants <50 years; (3) intervention group was receiving creatine monohydrate and the comparator group was receiving placebo; (4) evaluation of fat mass was performed via dual x-ray absorptiometry (DXA), bioelectrical impedance (BIA), hydrodensitometry, magnetic resonance imaging (MRI), computed tomography (CT) scan, or air displacement plethysmography (Bod Pod); and (5) a minimum study duration of 4 weeks. Studies were excluded if: (1) they were not RCTs; (2) had no full text; or (3) had subjects with any kind of dietary restrictions (i.e., vegans/vegetarians).
2.2. Data Extraction and Risk of Bias
Data was independently extracted by two investigators (K.P. and F.R.). Name of the first author, publication date, country of origin, study design, participant age, sex, and health status, sample size, outcomes assessed, dose and duration of creatine supplementation, fat mass assessment tool, and dietary intake assessment, were among the information that was extracted. A third investigator (D.G.C.) settled disagreements between the authors. Version 2 of the Cochrane risk-of-bias 2 instrument for randomized trials (RoB2) was used to evaluate the quality of the included studies, and it was reviewed by two independent reviewers (K.P. and S.C.F.). Appraisal of risk of bias using the RoB2 tool included the assessment of the following domains of bias in RCTs: (1) randomization process, (2) deviations from intended interventions, (3) missing outcome data, (4) measurement of the outcome, and (5) selection of the reported result. Study quality was categorized as either low risk of bias, considerable concerns, or high risk of bias using the RoB2 tool rating system.
2.3. Statistical Analysis
The mean differences between groups were calculated by comparing changes in outcomes from baseline to follow-up, treating quantitative data as continuous measurements. Standardized mean differences were employed when measurement units were inconsistent (e.g., body fat % changes mixed with absolute body fat kilogram changes) and could not be changed to the units needed for the analyses. The inverse-variance approach and the random-effects model were used to determine statistical significance. Standard deviations and missing data for any changes between baseline and follow-up outcome data were determined by deriving a correlation coefficient of 0.5, considering that a value of standard deviation change from baseline derived from an included study was not provided.
Utilizing the overlap of their 95% confidence intervals (CIs) and expressing the results as a measurement of Cochran's Q (χ2 test) and I2, statistical heterogeneity of outcome measurements across included studies was evaluated. Low heterogeneity was considered when I2 levels were <50%, moderate heterogeneity between 50% to 74.9%, and high heterogeneity ≥75%. Subgroup analyses based on age (<40 years vs 41-49 years), sex (males only vs females only vs mixed sexes), fat mass assessment tool (DXA vs. BIA vs. Hydrodensitometry vs. Bod Pod), body mass index (BMI) (<25 kg/m2 vs. ≥25 kg/m2), creatine monohydrate duration (< 8 weeks vs ≥ 8 weeks) and dose (≤ 5 g/d vs > 5 g/d) were performed. Additionally, sensitivity analyses were performed to evaluate the robustness of reported statistical results by discounting the effects of lack of dietary intake assessment, participants with comorbidities, and studies with increased risk of bias. The meta-analyses were synthesized using Cochrane’s Review Manager (RevMan 5.4.1) software.
4. Discussion
This is the first meta-analysis to examine the efficacy of resistance exercise and creatine supplementation on measures of fat mass in adults < 50 years of age. Results showed that the combination of resistance exercise and creatine supplementation (≥ 4 weeks) significantly reduced body fat % by 1.19% (p=0.006) and also led to a small, non-significant reduction in absolute fat mass (-0.09 kg; p=0.88) compared to resistance exercise alone. Variables such as age (< 40 years: p=0.18; 41-49 years: p=0.88), sex (females only: p=0.84; males only: p=0.17; females and males combined: p=0.65), fat mass assessment tool (p=0.36 to 0.65), creatine dosage (< 5 grams: p=0.43; ≥ 5 grams: p=0.26) and duration of creatine supplementation (< 8 weeks: p=0.63; ≥ 8 weeks: p=0.18) did not alter these findings (p>0.05)..
These reductions in fat mass from resistance exercise and creatine supplementation in adults < 50 years are compatible to our previous meta-analysis findings in adults ≥ 50 years (absolute fat mass: -0.50 kg; p=013; body fat %: -0.55; p=0.04) using similar inclusion criteria. Collectively, results across meta-analyses indicate that the combination of resistance exercise and creatine supplementation produces a very small reduction in body fat % in adults ≥ 18 years. These findings refute the common belief held by many exercising individuals that creatine supplementation increases fat mass over time [
15].
From a population health perspective, the combination of resistance exercise and creatine supplementation may have some (
albeit very small) application for helping attenuate global obesity rates and escalating healthcare costs. According to the 2023 World Obesity Atlas report [
29], over 4 billion people will be diagnosed with obesity by the year 2035, costing almost
$4 trillion annually. Obesity also contributes to other adverse conditions such as stroke, heart disease, type 2 diabetes, and different types of cancer [
30], putting substantial strain on the global healthcare system.
Mechanistically, the small reduction in body fat % from creatine may be related to its involvement in adipose tissue metabolism and whole-body energy expenditure [
11,
14]. There are two major types of adipose tissue, white adipose tissue (WAT) and brown adipose tissue (BAT) [
31]. Traditionally, WAT is purported to store energy and BAT plays a critical role in non-shivering thermogenesis through both independent and dependent effects of uncoupling protein-1 (UCP-1) [
11]. However, there is a growing body of evidence that WAT is not inert and can be altered to simulate the phenotypical and functional characteristics of BAT [
31], through a process known as “browning” [
32]. This process activates beige adipocytes residing in WAT depots [
32]. Due to the quantity of WAT an individual possess, activation of this type of adipose tissue may play an important role in thermoregulation and has the potential to significantly increases daily whole-body energy expenditure [
31]. Therefore, increasing properties of WAT could lead to decreases in fat mass over time. In Sprague-Dawley rats (16 male, 16 female), creatine supplementation (2.5 g/L, 5 g/L, 10 g/L that corresponds to ~2.5, 4.7, and 9.0 g/day in an average 70 kg human) for 8 weeks significantly increased WAT mitochondrial markers (COXIV, PDH-E1 α) and that these mitochondrial markers respond in a sex and depot specific manner [
31]. For example, in inguinal WAT the female rats had significantly elevated increases in COXIV, PDH-E1 α, and cytochrome C protein content, while in the male rats, gonadal WAT specific increases in COXIV and PDH-E1 α protein content were increased [
31]. Furthermore, in transgenic mice lacking either the adipose tissue creatine transporter (Adipo-CrT knockout) or the ability to endogenously synthesize creatine (Adipo-Gatm knockout) both leading to low total creatine levels, had significant reductions in beige adipose tissue oxidative metabolism and whole-body energy expenditure resulting in an increase in fat mass compared to control mice [
13,
14]. Others has shown that a reduction in creatine in beige adipose tissue impairs energy expenditure and adipose metabolic rate in mice [
11,
33]. In examining the effects of creatine supplementation (20 g/day for 5 days followed by 5g/day for 51 days) in adults with total cholesterol levels > 200 mg/dL, Earnest et al. [
34] showed that creatine significantly reduced plasma triglyceride levels by 23% over time.
Beyond these potential direct mechanisms, creatine supplementation may indirectly have a favorable effect on fat mass through its positive effect on lean tissue mass and muscle accretion. Several meta-analyses have been performed collectively showing that the combination of creatine supplementation and resistance exercise increases measures of whole-body lean tissue mass by ~1.37 kg compared to placebo and resistance exercise [
35,
36,
37,
38,
39]. Furthermore, Burke et al. [
40] performed a systematic review and meta-analysis involving 10 studies and found significant improvements in direct measures of limb muscle hypertrophy (0.10-0.16 cm; as measured using ultrasound and peripheral quantitative computed tomography [pQCT]) in the upper- and lower-body from creatine supplementation and resistance exercise compared to resistance exercise and placebo. Interestingly, the lone study that used pQCT showed that creatine supplementation (52 weeks) increased lower-limb muscle density (Δ +0.83 ± 1.15 mg·cm-3; p = 0.016) compared to placebo (Δ -0.16 ± 1.56 mg·cm-3). Mechanistically, these lean tissue mass and muscle improvements may be related to creatine increasing cellular hydration status, high-energy phosphate metabolism (phosphocreatine content and recovery), glycogen synthesis, satellite cell proliferation and activity, growth factor production and expression (i.e., insulin-like growth factor-1), myogenic transcription factor expression (Myf5, Mrf4, MyoD, myogenin), protein kinases downstream in the mammalian target of rapamycin (mTOR) signaling pathway which are involved in translation and decreasing measures of inflammation, oxidative stress (reactive oxygen species) and protein catabolism (whole-body leucine oxidation, urinary excretion of 3-methylhistidine) [
36]. The significant increases in whole-body lean tissue mass, limb muscle hypertrophy and muscle density from creatine supplementation may increase energy expenditure which could reduce fat mass over time [
41]. Our results indirectly support this notion as there was a statistically significant reduction in body fat % with only a small, non-significant change, in fat mass over time. Unfortunately, the mechanistic effects of creatine, with and without resistance exercise, in healthy adults (≥ 18 years) is unknown.
Author Contributions
Conceptualization, D.G.C., S.C.F., K.P; methodology, D.G.C., S.C.F. K.P, F.R; validation, S.C.F, K.P.; formal analysis, S.C.F., K.P. writing—original draft preparation, all authors; writing—review and editing, all authors.
Conflicts of Interest
S.C.F. previously served as a scientific advisor for a company that sold creatine ; has received creatine donations for scientific studies ; and sells creatine education resources. D.G.C. has conducted industry sponsored research involving creatine supplementation and received creatine donations for scientific studies and travel support for presentations involving creatine supplementation at scientific conferences. In addition, D.G.C. serves on the Scientific Advisory Board for Alzchem (a company that manufactures creatine) and as an expert witness/consultant in legal cases involving creatine supplementation. B.C. has received grants and contracts to conduct research on dietary supplements ; has served as a paid consultant for industry; has received honoraria for speaking at conferences and writing lay articles about sports nutrition ingredients and topics; and has served as an expert witness on behalf of the plaintiff and defense in cases involving dietary supplements. S.M.O. serves on the Scientific Advisory Board for Alzchem (a company that manufactures creatine). SMO owns patent “Sports Supplements Based on Liquid Creatine” at European Patent Office (WO2019150323 A1), and active patent application “Synergistic Creatine” at UK Intellectual Property Office (GB2012773.4). SMO has served as a speaker at Abbott Nutrition, a consultant of Allied Beverages Adriatic and IMLEK, and has received research funding related to creatine from the Serbian Ministry of Education, Science, and Technological Development, Provincial Secretariat for Higher Education and Scientific Research, AlzChem GmbH, KW Pfannenschmidt GmbH, ThermoLife International LLC, and Hueston Hennigan LLP. K.P and F.R. declare no conflicts.